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The CCR5 molecule, a chemokine receptor, is the most important co-receptor for macrophage-tropic HIV-1. A 32-bp
deletion in the gene encoding CCR5 (CCR5-del32) confers nearly complete resistance to HIV-1 infection in
homozygotes, and slows the rate of progression to AIDS in heterozygous adults. The aim of this study was to
describe the CCR5 genotypes and the characteristics of HIV disease progression in perinatally infected children.
From a total of 51 children analyzed for the CCR5-del32 mutation, 18 (35%) were considered to be rapid progressors,
28 (55%) were moderate progressors and 5 (10%) were slow progressors. A portion of the CCR5 gene was amplified
by PCR from genomic DNA followed by agarose gel electrophoresis. Forty-nine children (96%) carried the homozygous
wild type genotype for CCR5 while 2 (4%) carried the heterozygous wt/del32 genotype. In the population studied,
the CCR5 genotype was unable to account for the differences in pattern of the disease progression among the three
groups (rapid, moderate and slow progressors), and the allele frequency of CCR5-del32 was too low to allow
statistical comparisons with adequate resolving power. Studies on larger populations may help to further elucidate
the role of this allele and other host factors in the regulation of HIV-1 pathogenesis in children.
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From the late nineties onwards, expressive advances in
healthcare practices concerning HIV-positive children have
led to changes in the clinical course of the illness, resulting in
lower morbidity and mortality [1].
HIV-1 infection in children takes a variable course, causing
early symptoms in approximately 20% (rapid progression) [2].
Most children show moderate progression of the illness, and a
small group remains asymptomatic for many years [3]. Several
factors contribute to this scenario, mainly linked to viral and
host characteristics. Regarding host factors, the pertinent
literature emphasizes the role of the CCR5 gene that encodes a
cell-surface, chemokine-receptor molecule which serves as a
co-receptor for macrophage-tropic strains of HIV-1 [4,5].
Homozygosity for the 32-bp deletion (del32/del32) in the
CCR5 gene confers a certain degree of resistance to HIV-1
infection, while heterozygosity (del32/wt) slows the rate of
progression to AIDS in adults [6,7].
To better understand the role of the del32 allele in HIV-1
disease progression in children, in the present study, we
evaluated the genotypes of the CCR5 co-receptor in children
exhibiting different time courses of progression to AIDS.
Materials and Methods
Study Population
The present study was conducted on HIV-infected children
attended at the Federal University of São Paulo (SP, Brazil),
enrolled from November 2001 to October 2003, during routine
clinical visits, which took place approximately every 2 months.
Signed, informed consent was obtained from the parents or
guardians of all 51  children enrolled in the study. The present
investigation and the protocols comply  with the Research
Ethics Committee of Federal University of São Paulo.
The demographic characteristics of the studied population
are provided in Table 1. All children enrolled had acquired the
infection by vertical transmission of HIV, and were analyzed
for CCR5 genotypes, CD4 nadir counts, immunological and
clinical categories and pattern of progression of HIV disease.
The revised CDC classification [8] was used to define clinical
categories and the degrees of  immunosupression based on
age-specific CD4 T-lymphocyte counts. Children were
considered to be either rapid, moderate or slow progressors
when they  exhibited clinical signs and symptoms of the
disease, or signs of  immunodeficiency, within the first two
years of life, between 2-8 years, and after 8 years of age,
respectively.
DNA Samples
DNA samples were obtained from PBMC using 4% saponin
and the QIAamp Blood  kit (QIAGENInc, Santa Clarita, C.A.,
USA), according to the manufacturers.
CCR5 Genotyping
A portion of the CCR5 gene was amplified by PCR utilizing
primers that flank the  32-bp deletion (P1(2975), 5´-
CAAAAAGAAGGTCTTCATTACACC – 3´and  P2(2976),
5´- CCTGTGCCTCTTCTTCTCATTTCG – 3´)[9]. Wild-type
and deleted  fragments of 189 and 157 bp, respectively, were
generated. The presence of both  fragments was considered
to represent heterozygosity (wt/del32). The PCR  reaction
mixture contained 0.25 mM DNTPs, 20 pmol of each primer,
and 0.5 Unit  of Taq polymerase in 1x reaction buffer
(Invitrogen). Each PCR amplification  consisted of 40 cycles
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as follows: the first 5 cycles at 94°C for 1 min, 55°C for 1 min
and 72°C for 1.5 min; 35 cycles at 94°C for 30 s, 60°C for 30 s,
and 72°C for 45 s, were carried out in a MasterCycler thermal
cycler (Eppendorf).
A 10 µL aliquot of each 25 µL PCR reaction mixture was run
on a 2.5% agarose gel electrophoresis and the appropriately
sized products were visualized under UV illumination after
staining with ethidium bromide (1 µg/mL). Molecular size marker
is indicated at right in basepairs (Figure 1).
Results
Forty-nine (96%) of the 51 infected children were
homozygous for the wild-type CCR5 genotype (wt/wt), and 2
(4%) were heterozygous for the del32 genotype (wt/del32).
We found no homozygosity for the mutated allele (del32/del32)
(Table 2). Between the two heterozygotes, one was a
moderately symptomatic rapid progressor and the other was
a severely symptomatic moderate progressor. The rapid
progressor was a three year-old boy who showed the first
symptoms at 7 months of age and the moderate progressor
was a seven year-old boy who showed the first symptoms at
3 years of age. Most children showed a pattern of moderate
progression (n=28; 55%); 18 children (35%) were rapid
progressors, and 5 (10%) were slow progressors.
There were no significant differences among the slow,
moderate and rapid progressors in terms of their CCR5
genotypes or in terms of age, CD4 nadir values and
immunological classification. More children classified as rapid
progressors had reached clinical category C (n=9; p<0.05),
compared to moderate and slow progressors.
Discussion
Several large studies of the effects of CCR5 genotypes on
HIV disease progression have been undertaken in adults
[6,10,11]; however, less data are available for children [12,13].
There is a high frequency of the CCR5-del32 allele genotype
among Caucasians from North America and Europe, 1% of
them possessing the homozygous allele, while 10 and 20%,
respectively, exhibit the heterozygous allele [14,15]. The
frequency of the heterozygous allele among Afro-Americans
is 6%, with 7% among Hispanics, 13% among native Americans
and 0.6% among Asians [16]. The highest recorded allele
frequency is 20.93%, found in the Ashkenazi Jews, known to
be highly endogamous [17].
The results of the present study showed that the normal
CCR5 genotype was the most frequent among our outpatient
HIV-1 children.
The prevalence of the heterozygous allele in this group of
children of different ethnic origins was 4%, comparable to the
findings for various studies in Brazilian adults (5% in blood
donors [18], and 5.1% in patients with falciform anemia [19]).
Silva et al. reported a 6.5% incidence of the heterozygous
genotype among blood donors from São Paulo city, Brazil.
Many studies have been performed to evaluate whether
heterozygosity of the CCR5-del32 allele genotype affects the
vertical transmission of HIV-1, or whether it affects disease
progression [6,16,20-22]. One meta-analysis has revealed that
perinatal infection is not significantly altered by
heterozygosity for CCR5-del32 in children [23]. Another
metaanalysis has been performed among 10 studies including
1317 HIV-1 infected children, addressing the effects of CCR5-
del32. For progression to clinical AIDS, CCR5-del32 showed
an overall non-significant trend for protection (hazard ratio
0.84, 95% confidence interval 0.58-1.23).
However, survival analyses showed a statistically
significant time-dependence. The CCR5-del32 genotype was
associated with a decreased risk of death among perinatally
infected children, although only during the first years of life
[21].
Multiple factors may affect HIV-1 disease progression in
perinatally infected children, such factors include in utero
versus intrapartum infection, maternal disease status at the
time of delivery [24], therapeutic and prophylactic treatment
of the mother and infant, and host human leucocyte antigen
(HLA) genotype 11. In our studied population, the CCR5
genotype was unable to account for the difference in pattern
of disease progression among the three groups (rapid,
moderate and slow progressors). However, we can not exclude
a potential role for these genetic characteristics, since sample
size in our study was limited, and the allele frequency of CCR5-
del32 was too low to allow statistical comparisons with
adequate resolving power. Studies with larger populations
may further elucidate the role of this allele and other host
factors in the regulation of HIV-1 pathogenesis in children.
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Figure 1. CCR5 genotypes among HIV-1 infected children.
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Total number of individuals (N) 51
Gender Female 32 (63%)
Median age (range) 9 (3-16)
Median CD4 count (range) 842 (20-1735)
Median count CD4 nadir 432 (3-1613)
Clinical category* N %
A 9 18
B 20 39
C 19 37
N 3 6
Immunological category*
1 9 18
2 19 39
3 21 43
*Centers for Disease Control [9].
Type of progression to AIDS
CCR5 genotype Rapid Moderate Slow
Homozygous wild type (wt/wt) 17 27 5
Heterozygous (del32/wt) 1 1 0
Homozygous mutant (del32/del32) 0 0 0
Total number of cases 18 28 5
